reference/34478848

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/34478848

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase I\|Journal Article
endingPage	913
issn	0278-0232 1099-1069
issueIdentifier	5
pageRange	906-913
publicationName	Hematological Oncology
startingPage	906
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_ee72cca4fd7f5aead55d62d7b3df2384
bibliographicCitation	Berenson JR, Kim C, Bujarski S, To J, Spektor TM, Martinez D, Turner C, Ghermezi M, Eades BM, Swift RA, Schwartz G, Eshaghian S, Moss RA, Lim S, Vescio R. A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients. Hematol Oncol. 2022 Dec;40(5):906–13. doi: 10.1002/hon.3066. PMID: 35946431.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ff373bea8c48baa1af9cf69d98ebcaab http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-1587-6104 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6f272fff1e6d8fd83368a1c398d80b0c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7a775037a001eb915329a7a9625095e0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_eddd2ea69da488b061c17ee5d36eff05 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3d9e6b6a8ad61829cc54153ff06f01aa http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8c575dc03f87fd3ac7b8b56b683046ad http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9064318c85a6d48a41c7c1bd57375f60 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_810a99eac09552312bc7c32c1f4e235c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_aa9cfa4c117e882de2c348c976474cfc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f4d755bd6a208a9da61f623ddcec828f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_89e8a5729b68f861428ad4471a844938 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1a118cccf27259710be2b5049074418d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9c8f801211579616bde25476ed00b8a2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e1a8f31b2b0d2e256ecf7a3c03abbdd5
date	2022-08-14^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/35946431 https://doi.org/10.1002/hon.3066
isPartOf	https://portal.issn.org/resource/ISSN/0278-0232 https://portal.issn.org/resource/ISSN/1099-1069 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/4074
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients
discusses	http://id.nlm.nih.gov/mesh/M0479831
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D009101Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D000077269 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D006801
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10064 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10308 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID25126798 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8561 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8530 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID216326 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6873 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8911 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_2ab607cfd59f1fbe11e5ae4e6b36603c http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_3.4.25.1 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6741 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5743

Showing number of triples: 1 to 53 of 53.